Hematopoietic stem cell transplantation for systemic sclerosis: If you are confused, remember: "It is a matter of the heart"

Journal of Rheumatology

Volumn 39, Issue 2, 2012, Pages 206-209

  Burt, Richard K ^a   Shah, Sanjiv J ^a   Gheorghiade, Mihai ^a   Ruderman, Eric ^a   Schroeder, James ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; PLACEBO; RITUXIMAB; THYMOCYTE ANTIBODY;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CONSTRICTIVE PERICARDITIS; ECHOCARDIOGRAPHY; EDITORIAL; FORCED VITAL CAPACITY; HEART CATHETERIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL PNEUMONIA; MORTALITY; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SYSTEMIC SCLEROSIS; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; SCLERODERMA, SYSTEMIC;

EID: 84856556149     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111302     Document Type: Editorial

References (21)

1. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
2. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34. (Pubitemid 350127847)
3. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70. (Pubitemid 44955900)
4. Broad K, Pope JE. The efficacy of treatment for systemic sclerosis interstitial lung disease: Results from a meta-analysis. Med Sci Monit 2010;16:RA187-90.
5. Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008;10:R124:1-9.
6. Launay D, Marjanovic Z, de Bazelaire C, Florea L, Zohar S, Keshtmand H, et al. Autologous hematopoietic stem cell transplant in systemic sclerosis: Quantitative high resolution computed tomography of the chest scoring. J Rheumatol 2009;36:1460-3.
7. Tsukamoto H, Nagafuji K, Horiuchi T, Miyamoto T, Aoki K, Takase K, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 2006;65:508-14
8. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): An open-label, randomised phase 2 trial. Lancet 2011;378:498-506.
9. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007;110:1388-96. (Pubitemid 47281441)
10. Burt RK, Abinun M, Farge-Bancel D, Fassas A, Hiepe F, HavrdováE, et al. Risks of immune system treatments. Science 2010;328:825-6.
11. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008;299:925-36. (Pubitemid 351397068)
12. Loberiza FR Jr, Zhang MJ, Lee SJ, Klein JP, LeMaistre CF, Serna DS, et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 2005;105:2979-87. (Pubitemid 40446296)
13. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: An observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010;95:284-9.
14. Henes JC, Schmalzing M, Vogel W, Riemekasten G, Fend F, Kanz L, et al. Optimization of autologous stem cell transplantation for systemic sclerosis - A single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol 2012;39:269-75.
15. Frea S, Capriolo M, Marra WG, Cannillo M, Fusaro E, Libertucci D, et al. Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosis. Echocardiography 2011;28:860-9.
16. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
17. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997;36:239-43.
18. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006;174:1034-41. (Pubitemid 44684453)
19. Bush CA, Stang JM, Wooley CF, Kilman JW. Occult constrictive pericardial disease. Diagnosis by rapid volume expansion and correction by pericardiectomy. Circulation 1977;56:924-30. (Pubitemid 8243128)
20. Meune C, Vignaux O, Kahan A, Allanore Y. Heart involvement in systemic sclerosis: Evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 2010;103:46-52.
21. Scott PA, Morgan JM, Carroll N, Murday DC, Roberts PR, Peebles CR, et al. The extent of left ventricular scar quantified by late gadolinium enhancement MRI is associated with spontaneous ventricular arrhythmias in patients with coronary artery disease and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol 2011;4:324-30.